论文部分内容阅读
目的研究胃肠间质瘤(GISTs)基因突变与免疫组化表达的关系。方法分别对102例GISTs患者(GISTs组)及50例非GISTs间叶源性肿瘤患者(非GISTs组)的DOG1及CD117表达进行比较,检测GISTs组IGFIR表达情况,同时检测90例GISTs患者c-KIT及PDGFRA基因突变情况。结果 102例GISTs患者中DOG1阳性表达率为91.18%(93/102)、CD117为93.14%(95/102)、IGFIR为6.86%(7/102),50例非GISTs间叶源性肿瘤中DOG1阳性表达率为10.00%(5/50),CD117为18.00%(9/50),两组DOG1及CD117阳性率比较差异具有统计学意义(P<0.05)。结论检测DOG1及CD117可实现对胃肠间质瘤基因突变的有效诊断,而IGFIR考虑为野生型GISTs特异性的免疫组化指标以及潜在治疗靶点,应结合免疫组化表达情况对GISTs基因突变进行分析。
Objective To study the relationship between GISTs gene mutation and immunohistochemical expression in gastrointestinal stromal tumors (GISTs). Methods The expression of IGF1 and CD117 in 102 cases of GISTs and 50 cases of non-GISTs patients with non-GISTs (non-GISTs) were compared. The expression of IGFIR in GISTs was detected, and 90 cases of GISTs were tested for c- KIT and PDGFRA gene mutations. Results The positive expression rates of DOG1 in 102 GISTs were 91.18% (93/102), 93.14% (95/102) in CD117, and 6.86% (7/102) in IGFIR. Among 50 non-GISTs mesenchymal tumors, DOG1 The positive rates of DOG1 and CD117 were 10.00% (5/50) and 18.00% (9/50) respectively. There was significant difference between the two groups (P <0.05). Conclusion Detecting DOG1 and CD117 can effectively diagnose gastrointestinal stromal tumor gene mutations. However, IGFIR is considered as a specific immunohistochemical marker and a potential therapeutic target for wild type GISTs. Mutations in GISTs should be combined with immunohistochemical analysis Analyze.